Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 54(8): 3155-60, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20530224

ABSTRACT

Bioluminescence imaging is an innovative, noninvasive tool to analyze infectious disease progression under real-life conditions in small laboratory animals. However, the relevance of bioluminescence imaging to monitor invasive compared to noninvasive bacterial infections of the lung has not been examined so far. In the current study, we systematically evaluated the importance of bioluminescence imaging to monitor pneumococcal disease progression by correlating biophotonic signals with lung bacterial loads in two mouse strains (BALB/c, C57BL/6) infected with either self-glowing, bioluminescent serotype 19 Streptococcus pneumoniae causing focal pneumonia or serotype 2 S. pneumoniae causing invasive pneumococcal disease. The best correlations between bioluminescence signals and lung CFU counts were observed in BALB/c mice compared to C57BL/6 mice just on day 3 after infection with invasive serotype 2 S. pneumoniae, while excellent correlations between photon counts and bacterial loads were observed in isolated lungs of BALB/c and C57BL/6 mice, irrespective of the employed pneumococcal serotype. Moreover, good correlations between biophotonic signals and CFU counts were also observed in mice upon infection with serotype 19 S. pneumoniae causing focal pneumonia in mice, again with best correlation values obtained for BALB/c mice at day 3 postinfection. Collectively, we show that the relevance of biophotonic imaging to monitor S. pneumoniae-induced lung infections in mice is largely influenced by the disease model under investigation. The provided data may be important for studies of infectious diseases.


Subject(s)
Diagnostic Imaging/methods , Disease Models, Animal , Luminescent Measurements/methods , Photons , Pneumonia, Pneumococcal/microbiology , Streptococcus pneumoniae/isolation & purification , Streptococcus pneumoniae/pathogenicity , Animals , Colony Count, Microbial , Female , Humans , Image Processing, Computer-Assisted/methods , Lung/microbiology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Pneumonia, Pneumococcal/diagnosis , Serotyping , Streptococcus pneumoniae/classification , Virulence
2.
Antimicrob Agents Chemother ; 54(2): 707-17, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19917756

ABSTRACT

Daptomycin is a novel lipopeptide antibiotic with excellent activity against Gram-positive bacterial pathogens, but its therapeutic value for the treatment of invasive pneumococcal disease compared to that for the treatment of pneumococcal pneumonia is incompletely defined. We investigated the efficacy of daptomycin in two models of Streptococcus pneumoniae-induced lung infection, i.e., pneumococcal pneumonia and septic pneumococcal disease. Mice were infected with a bioluminescent, invasive serotype 2 S. pneumoniae strain or a less virulent serotype 19 S. pneumoniae strain and were then given semitherapeutic or therapeutic daptomycin or ceftriaxone. Readouts included survival; bacterial loads; and septic disease progression, as determined by biophotonic imaging. Semitherapeutic daptomycin treatment fully protected the mice against the progression of septic disease induced by serotype 2 S. pneumoniae, while therapeutic treatment of the mice with daptomycin or ceftriaxone led to approximately 70% or approximately 60% survival, respectively. In contrast, mice infected with serotype 19 S. pneumoniae developed severe pneumonia and lung leakage even in the presence of increased intra-alveolar daptomycin levels, resulting in only 40% survival, whereas the ceftriaxone-treated mice had 100% survival. Together, although daptomycin demonstrates little efficacy in the treatment of pneumococcal pneumonia, daptomycin is highly effective in preventing S. pneumoniae-induced septic death, thus possibly offering a therapeutic option for patients with life-threatening septic pneumococcal disease.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Daptomycin/therapeutic use , Pneumococcal Infections/drug therapy , Pneumonia, Pneumococcal/drug therapy , Sepsis/drug therapy , Streptococcus pneumoniae/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Daptomycin/pharmacology , Disease Models, Animal , Mice , Mice, Inbred C57BL , Pneumococcal Infections/microbiology , Pneumonia, Pneumococcal/microbiology , Sepsis/microbiology , Streptococcus pneumoniae/physiology
3.
BMC Mol Biol ; 8: 80, 2007 Sep 19.
Article in English | MEDLINE | ID: mdl-17880697

ABSTRACT

BACKGROUND: The Gateway recombinatorial cloning system allows easy and rapid joining of DNA fragments. Here we report the construction and evaluation of three different Gram-positive vectors that can be used with the Multisite Gateway cloning system to rapidly produce new gene arrangements in plasmid constructs for use in a variety of Gram-positive bacteria. RESULTS: Comparison of patterns of reporter gene expression with conventionally constructed clones show that the presence of residual recombination (att) sites does not have an effect on patterns of gene expression, although overall levels of gene expression may vary. Rapid construction of these new vectors allowed vector/gene combinations to be optimized following evaluation of plasmid constructs in different bacterial cells and demonstrates the benefits of plasmid construction using Gateway cloning. CONCLUSION: The residual att sites present after Gateway cloning did not affect patterns of promoter induction in Gram-positive bacteria and there was no evidence of differences in mRNA stability of transcripts. However overall levels of gene expression may be reduced, possibly due to some post-transcriptional event. The new vectors described here allow faster, more efficient cloning in range of Gram-positive bacteria.


Subject(s)
Bacillus subtilis/genetics , Cloning, Molecular/methods , Genetic Vectors/genetics , Listeria monocytogenes/genetics , Recombination, Genetic/genetics , Staphylococcus aureus/genetics , Bacillus subtilis/metabolism , Gene Expression , Genes, Reporter/genetics , Kinetics , Listeria monocytogenes/metabolism , Plasmids/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Staphylococcus aureus/metabolism , Time Factors
4.
J Antimicrob Chemother ; 56(4): 665-71, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16105852

ABSTRACT

OBJECTIVES: To utilize bioluminescence to follow the effect of ciprofloxacin challenge on Pseudomonas aeruginosa biofilms. METHODS: The Sorbarod continuous perfusion culture system was used for the cultivation of biofilms of a self-bioluminescent strain of P. aeruginosa PAO1. Biofilms were challenged with ciprofloxacin (5 mg/L) in the perfusing medium for 3 h and allowed to recover to pre-challenge population levels before initiation of a second 3 h challenge. In addition to determining eluate and biofilm cell survival by conventional viable plate counts, light output was monitored via a luminometer and a low-light-level ICCD camera, to give an indication of metabolism. The effect of drug challenge on biofilm structure was investigated using an environmental scanning electron microscope, which allowed discernment of changes to the three-dimensional biofilm architecture. RESULTS: On challenge with ciprofloxacin, eluate light output measurements declined to a lesser extent than viable counts for the same samples and also indicated that post-challenge recovery of the biofilm metabolism did not occur as rapidly as suggested by viable count data. Photon detection by ICCD camera allowed real-time, non-invasive imaging of metabolic activity within intact biofilms. CONCLUSIONS: The application of a bioluminescent reporter strain to biofilm research provides valuable real-time positional data on the efficacy of anti-biofilm treatment strategies.


Subject(s)
Biofilms/drug effects , Ciprofloxacin/pharmacology , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/physiology , Anti-Bacterial Agents/pharmacology , Luminescence , Luminescent Measurements , Pseudomonas aeruginosa/metabolism
5.
J Antimicrob Chemother ; 52(3): 511-3, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12888600

ABSTRACT

A bioluminescent clinical isolate of Streptococcus pneumoniae was used to test the real-time effects of the oxazolidinone antibiotic, linezolid, on metabolism compared with effects on cell replication. Viable counts and bioluminescence measurements showed that linezolid has little bactericidal effect, which was similar at minimum (6 mg/L), intermediate (13 mg/L) and maximum (20 mg/L) serum concentrations. The post-antibiotic effect, however, was shorter when measured by light output than by viable counts. The results demonstrate that bioluminescence provides a rapid and sensitive means of measuring the effect of antimicrobials on bacterial metabolism, and that the latter recovers earlier than commencement of cell replication after linezolid exposure.


Subject(s)
Acetamides/pharmacology , Anti-Bacterial Agents/pharmacology , Genes, Bacterial/genetics , Oxazolidinones/pharmacology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/genetics , Colony Count, Microbial , Culture Media , Genetic Markers , Linezolid , Luminescent Measurements , Microbial Sensitivity Tests , Operon/genetics
6.
FEMS Microbiol Lett ; 223(1): 95-9, 2003 Jun 06.
Article in English | MEDLINE | ID: mdl-12799006

ABSTRACT

A method was developed that enabled real-time monitoring of the uptake and survival of bioluminescent Escherichia coli O157 within the freshwater ciliate Tetrahymena pyriformis. Constitutively bioluminescent E. coli O157 pLITE27 was cocultured with T. pyriformis in nutrient-deficient (Chalkley's) and in nutrient-rich (proteose peptone, yeast extract) media. Non-internalised bacteria were inactivated by addition of colistin, indicated by a decline in bioluminescence. Protozoa were subsequently lysed with Triton X-100 which lead to a further drop in bioluminescence, consistent with release of live internal bacteria from T. pyriformis into the colistin-containing environment. Bioluminescence measurements for non-lysed cultures indicated that internalised E. coli O157 pLITE27 cells were only slowly digested by T. pyriformis, in both media, over the time period studied. The results suggest that bioluminescent bacteria are useful tools in the study of bacterial intra-protozoan survival.


Subject(s)
Escherichia coli O157/growth & development , Escherichia coli O157/genetics , Luminescent Proteins/genetics , Tetrahymena pyriformis/microbiology , Animals , Colony Count, Microbial , Microbiological Techniques
SELECTION OF CITATIONS
SEARCH DETAIL
...